KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-Current Assets (2016 - 2025)

Biomarin Pharmaceutical's Non-Current Assets history spans 17 years, with the latest figure at $3.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 3.09% year-over-year to $3.6 billion, compared with a TTM value of $14.7 billion through Dec 2025, down 3.38%, and an annual FY2025 reading of $3.6 billion, down 3.09% over the prior year.
  • Non-Current Assets for Q4 2025 was $3.6 billion at Biomarin Pharmaceutical, down from $3.8 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $3.9 billion in Q1 2024, with the low at $3.5 billion in Q1 2021.
  • Average Non-Current Assets over 5 years is $3.7 billion, with a median of $3.7 billion recorded in 2021.
  • Year-over-year, Non-Current Assets soared 34.9% in 2021 and then decreased 5.36% in 2025.
  • Tracing BMRN's Non-Current Assets over 5 years: stood at $3.7 billion in 2021, then dropped by 2.86% to $3.6 billion in 2022, then grew by 7.23% to $3.9 billion in 2023, then fell by 3.32% to $3.8 billion in 2024, then fell by 3.09% to $3.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Non-Current Assets are $3.6 billion (Q4 2025), $3.8 billion (Q3 2025), and $3.7 billion (Q2 2025).